Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 12:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Moderate to Severe Chronic Pain Clear all
Completed Phase 2 Interventional Results available

Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.

NCT00740779
View directory record Official record
Conditions
Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Interventions
Silodosin 8 mg, Placebo, Silodosin 4 mg
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
22
States / cities
San Diego, California • Denver, Colorado • Columbus, Georgia + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2012 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza

NCT00640042
View directory record Official record
Conditions
Pain
Interventions
morphine sulfate extended release capsules
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
1,570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
378
States / cities
Adamsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 314 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain

NCT01428583
View directory record Official record
Conditions
Chronic Noncancer Pain
Interventions
oxycodone HCl and naltrexone HCl extended-release capsules
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
32
States / cities
DeLand, Florida • Jacksonville, Florida • Jupiter, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2016 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 3 Interventional Results available

Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Pain

NCT01298765
View directory record Official record
Conditions
Pain, Low Back Pain, Osteoarthritis, Neuropathic Pain
Interventions
BEMA Buprenorphine
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
26
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain

NCT01619839
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
NKTR-181, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
34
States / cities
Mobile, Alabama • Tucson, Arizona • Garden Grove, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2021 · Synced Jun 10, 2026, 12:42 PM EDT
Terminated Phase 3 Interventional

Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Non-Malignant Pain

NCT00126763
View directory record Official record
Conditions
Pain
Interventions
Fentanyl Transdermal Matrix Patch ZR-02-01
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
Phoenix, Arizona • Loma Linda, California • Marietta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

NCT01709214
View directory record Official record
Conditions
Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Interventions
Cebranopadol (GRT6005) Low-Dose Range, Cebranopadol (GRT6005) High-Dose Range, Placebo, Oxycodone CR
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
83
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 2 Interventional

Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Osteoarthritis (OA) Pain

NCT00108771
View directory record Official record
Conditions
Pain
Interventions
ZR-02-01 Fentanyl Transdermal Matrix Patch, Placebo Patch
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
13
States / cities
Phoenix, Arizona • San Diego, California • Upland, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 3 Interventional Results available

Long-term Open-Label Safety Study to Evaluate EN3409

NCT01755546
View directory record Official record
Conditions
Low Back Pain, Osteoarthritis, Neuropathic Pain
Interventions
EN3409
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
57
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain

NCT01081912
View directory record Official record
Conditions
Back Pain Lower Back Chronic
Interventions
Placebo, Hydrocodone bitartrate
Drug
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
51
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Anaheim, California + 47 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 3 Interventional Results available

An Open-label, 8-week Safety, Efficacy, and Assessment of Cooling Methods for Administration of CNTX-4975-05 for Knee OA

NCT03661996
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
CNTX-4975-05, Lidocaine without epinephrine, ElastoGel, Breg Ice Water Pump
Drug · Device
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
40 Years to 95 Years
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
28
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Jun 10, 2026, 12:42 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.

NCT03802227
View directory record Official record
Conditions
Moderate to Severe Chronic Pain
Interventions
NKTR-181, Oxycodone IR
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Jun 10, 2026, 12:42 PM EDT
Terminated Phase 2 Interventional

A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis

NCT01094262
View directory record Official record
Conditions
Osteoarthritis, Osteoarthritis, Knee, Pain, Arthralgia, Joint Pain
Interventions
Oxycodone CR (standard pain medication), JNJ-42160443, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
40 Years to 80 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
36
States / cities
Tucson, Arizona • Carmichael, California • Pismo Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.

NCT01400139
View directory record Official record
Conditions
Chronic Nonmalignant and Nonneuropathic Pain
Interventions
Hydrocodone bitartrate q24h film-coated tablets
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
922 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Jun 10, 2026, 12:42 PM EDT
Withdrawn Phase 4 Interventional

Pharmacokinetic,Safety and Exploratory Efficacy of RECTIV® in Adolescents With Chronic Anal Fissure

NCT01920074
View directory record Official record
Conditions
Anal Fissure
Interventions
Nitroglycerin Ointment 0.4%
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
12 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
6
States / cities
Los Angeles, California • Miami, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 3, 2015 · Synced Jun 10, 2026, 12:42 PM EDT
Terminated Phase 4 Interventional Results available

A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer

NCT00381095
View directory record Official record
Conditions
Bone Neoplasms, Pain, Intractable, Cancer
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
8
States / cities
Celebration, Florida • Kissimmee, Florida • Pensacola, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 3 Interventional Results available

A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

NCT01571362
View directory record Official record
Conditions
Chronic Pain, Low Back Pain, Analgesia
Interventions
ALO-02, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
52
States / cities
Mobile, Alabama • Goodyear, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of EN3324 (Axomadol) in Subjects With Chronic Low Back Pain

NCT01043263
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
EN3324 (axomadol), Placebo
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
59
States / cities
Phoenix, Arizona • Tucson, Arizona • Tuscon, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Jun 10, 2026, 12:42 PM EDT
Completed No phase listed Observational

Characterization & Treatment of Chronic Pain After Moderate to Severe TBI

NCT03739307
View directory record Official record
Conditions
Traumatic Brain Injury, Pain
Interventions
Not listed
Lead sponsor
Craig Hospital
Other
Eligibility
16 Years and older
Enrollment
3,805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
13
States / cities
Birmingham, Alabama • Englewood, Colorado • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain

NCT02367820
View directory record Official record
Conditions
Low Back Pain, Chronic Pain
Interventions
NKTR-181 BID tablets
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
56
States / cities
Saraland, Alabama • Phoenix, Arizona • Tempe, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Jun 10, 2026, 12:42 PM EDT
Not listed Phase 2 Interventional

Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis

NCT04885972
View directory record Official record
Conditions
Osteoarthritis, Knee, Knee Osteoarthritis, Knee Pain Chronic
Interventions
Resiniferatoxin, Zilretta, Placebo
Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
La Mesa, California • Pasadena, California • Oak Brook, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced Jun 10, 2026, 12:42 PM EDT
Completed Phase 3 Interventional

Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain

NCT01427270
View directory record Official record
Conditions
Low Back Pain
Interventions
Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
170
States / cities
Alabaster, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 137 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Jun 10, 2026, 12:42 PM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)

NCT00964990
View directory record Official record
Conditions
Pain, Neuralgia, Postherpetic, Neuralgia, Mononeuropathies
Interventions
JNJ-42160443, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 80 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Redondo Beach, California + 37 more
Source: ClinicalTrials.gov public record
Updated May 1, 2016 · Synced Jun 10, 2026, 12:42 PM EDT
Recruiting Phase 1Phase 2 Interventional

Treatment of Moderate to Severe Refractory Crohn's Disease

NCT06721962
View directory record Official record
Conditions
Crohns Disease
Interventions
TRX103, Cyclophosphamide
Biological · Drug
Lead sponsor
Tr1X, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
13
States / cities
Scottsdale, Arizona • Sacramento, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Jun 10, 2026, 12:42 PM EDT